Input 2021.02.15 14:42 | Revision 2021.02.15 15:06
Celltrion is preparing to ship 100,000 people… Production for 3 million people per year
The Centers for Disease Control and Prevention of the Korea Centers for Disease Control and Prevention announced this at a regular briefing on the afternoon of the 15th. Medical institutions in need of treatment can be supplied to patients from the 17th by applying to Celltrion from the 16th. Details on the supply of treatments will be announced by local governments in cities and provinces on this day.
Treatment targets are limited to moderately ill patients and high-risk mildly ill patients who are approved by the Ministry of Food and Drug Safety. Specifically, among patients who have not had symptoms for more than 7 days and do not require oxygen therapy, they are 60 years of age or older, or have underlying diseases of at least one of cardiovascular disease, chronic respiratory disease, diabetes, and hypertension.
It is restricted to use in general mild patients except high-risk groups. This is because a statistically significant treatment effect could not be confirmed because sufficient number of mild patients could not be secured in clinical trials. Earlier, the Ministry of Food and Drug Safety said, “Generally mild patients excluding high-risk patients can not use it in principle even if they want to use it,” he said. .
Currently, Celltrion has completed production and can supply 100,000 people. The company said it could produce up to 3 million people per year.
The manufacturing cost is known to be around 400,000 won per person, but as a result of the promotion of the application of health insurance benefits by the Agency for Disease Control and Prevention, free supply is possible. One dose is 40 mg per 1 kg of patient’s body weight and is administered intravenously for about 90 minutes.